RxDoctor Payments Data

Louis Coates, DO

Family Medicine · Garland, TXNPI 1366540791

Payments from drug & device makers

$10,186in general payments, 2019–2025

Across 618 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$918
  • Novo Nordisk$763
  • GSK$548
  • Esperion Therapeutics, Inc.$402
  • Johnson & Johnson$396
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$10,07499%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)92$1,164
AstraZeneca56$918
Novo Nordisk49$763
GSK33$548
Esperion Therapeutics, Inc.30$402
Johnson & Johnson24$396
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$381
Amgen(2 entities)21$378
Lilly USA, LLC22$344
Axsome Therapeutics, Inc.18$332
Pfizer15$268
Bayer14$246
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$224
Novartis11$217
Otsuka America Pharmaceutical, Inc.16$209
Merck13$203
Kowa Pharmaceuticals America, Inc.12$182
Corcept Therapeutics8$179
Amarin Pharma, Inc.9$179
Eisai Inc.13$179
Ironwood Pharmaceuticals, Inc9$168
Lundbeck LLC7$157
Astellas Pharma US Inc4$154
Supernus Pharmaceuticals, Inc.8$145
Corium, LLC6$143
Paratek Pharmaceuticals, Inc.7$134
Takeda Pharmaceuticals U.S.A., Inc.7$115
Genentech USA, Inc.5$99
Phathom Pharmaceuticals, Inc.4$95
Arbor Pharmaceuticals, Inc.6$88
Boehringer Ingelheim5$86
Idorsia Pharmaceuticals US Inc4$81
Tris Pharma Inc4$74
Althera Pharmaceuticals LLC5$67
Exact Sciences4$63
Antares Pharma, Inc.3$61
Bausch Health US, LLC3$59
Aytu Biopharma, Inc.4$57
Scilex Pharmaceuticals Inc.3$52
Clarus Therapeutics Inc.3$43
Biogen2$42
E.r. Squibb & Sons, L.L.C.2$41
Neos Therapeutics, LP2$36
Abiomed1$35
Si-bone, Inc.1$32
Currax Pharmaceuticals LLC2$25
Cardiovascular Systems Inc.1$25
VBI Vaccine (delaware) Inc.1$23
Xeris Pharmaceuticals, Inc.1$22
Arcutis Biotherapeutics, Inc.1$21
Noven Therapeutics, LLC1$21
Adlon Therapeutics L.p.1$20
Jazz Pharmaceuticals Inc.1$20
Seqirus USA Inc1$19
Cipher Pharmaceuticals US LLC1$19
Hikma Pharmaceuticals USA1$18
IBSA Pharma Inc.1$18
Shire North American Group Inc1$18
Collegium Pharmaceutical, Inc.1$17
Sanofi-aventis U.S. LLC1$16

How this compares

$10,186 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$287,096
Medicare patients
451
Services billed
4,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$143,582
MounjaroTirzepatide111$133,094
EliquisApixaban114$116,115
FarxigaDapagliflozin Propanediol52$66,795
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$54,658
Tresiba Flextouch U-200Insulin Degludec16$47,943
XareltoRivaroxaban36$38,983
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$21,972
JanuviaSitagliptin Phosphate16$16,182
JanumetSitagliptin Phos/Metformin Hcl14$15,162
MyrbetriqMirabegron16$13,690
LinzessLinaclotide20$12,648
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$11,157
Atorvastatin Calcium898$6,834
Ezetimibe391$6,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$763$143,582124 claims
Lilly USA, LLCMounjaro$344$133,094111 claims
PfizerEliquis$268$116,115114 claims
AstraZenecaFarxiga, Breztri Aerosphere$918$88,76885 claims
GSKTrelegy Ellipta$548$54,65872 claims
Johnson & JohnsonXarelto$396$38,98336 claims
MerckJanuvia, Janumet$203$31,34430 claims
AbbVieLinzess, Synthroid$1,164$18,44590 claims
Astellas Pharma US IncMyrbetriq$154$13,69016 claims
Sanofi-aventis U.S. LLCLantus$16$4,23925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →